Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop
into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who
have myelodysplastic syndrome.